

BAYER'S ONCOLOGY INDUSTRY TASKFORCE SUBMISSION

Bayer Australia joined the Oncology Industry Taskforce because it is aligned with its aims of reimbursing cost effective oncology medicines to allow Australians access to innovative treatments in a timely manner. In parallel with this, the Company has constructively explored the hurdles that face Government and patients in addressing access to medicines.

Working closely with the medical community, patient groups and Government, Bayer Pharmaceuticals makes available medicines to help Australians live better and longer.

Bayer Pharmaceuticals' commitment to scientific research started with the discovery of Aspirin in 1897 and continues today with research to develop treatments for liver and kidney cancer and new ones for the prevention of blindness and stroke prevention.

Bayer is committed to bringing to market innovative treatments for bowel, prostate, stomach and thyroid cancers in the future.

The Company is also committed to working closely with regulators, the Health Department, the independent PBAC and elected Government officials to ensure patients receive access to new cost effective oncology treatments that extend life and improve quality of life.
